Market Research Blog

[250 Pages Report] As per comprehensive research conducted by ESOMAR-certified consulting firm FMI, the global Transcatheter Heart Valve Replacement (TAVI) market is projected to witness robust growth during the forecast year 2021-2031. The report emphasizes on providing key insights into diverse features including demand, product developments, revenue generation, and sales in the Transcatheter Heart Valve Replacement (TAVI) market.

The study offers a detailed analysis of dynamics including driver, restraints, opportunities, and challenges, and also highlights their consequent impact on the market.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-537

Advent of Telehealth and Virtual Care to Create Tailwind for the Transcatheter Heart Valve Replacement (TAVI) Market Growth

Digitization is making deeper inroads across diverse industries, such as healthcare, owing to the increasing penetration of the internet and smartphones across the world.

During the COVID-19 outbreak, healthcare practitioners and patients realized the importance of digitization and encouraged them to adopt virtual methods of patient examination and consultation to counter the regulations concerning social distancing. This gave rise to a new medical domain, Telehealth.

Since the outbreak, telehealth have gained immense popularity, especially among the geriatric population, owing to the convenience associated with it. Hence, increasing adoption of telehealth across radiology, behavioral health, cardiology, and online consultation is expected to create lucrative opportunities for growth in the Transcatheter Heart Valve Replacement (TAVI) market.

Key Transcatheter Heart Valve Replacement (TAVI) Market Takeaways and Projections

• The U.S. is estimated to continue dominating the North America market, projecting fastest growth in the region through 2031.
• Germany Transcatheter Heart Valve Replacement (TAVI) market is forecast to register robust growth in Europe, accounting for a significant share in the region between 2021 and 2031.
• China is expected to account for the maximum revenue share in the East Asia market, exhibiting the fastest sales growth during the assessment period.
• India is forecast to emerge as a highly remunerative market in South Asia, contributing for the largest sales in the region over the coming 10-years.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-537

Report Benefits & Key Questions Answered

• Transcatheter Heart Valve Replacement (TAVI) Historical Market Outlook: Future Market Insight’s analysis examines vital dynamics, such as drivers, opportunities, and challenges in the Transcatheter Heart Valve Replacement (TAVI) market. It also studies the impact of these dynamics on the market for the previous assessment period 2016-2020 to forecast the scope of market growth over the coming forecast period 2021-2031.
• Transcatheter Heart Valve Replacement (TAVI) Demand-Supply Assessment: The latest study published by FMI offers in-depth insights into governing factors facilitating the demand outlook of the Transcatheter Heart Valve Replacement (TAVI) market. As per the survey, Transcatheter Heart Valve Replacement (TAVI) sales will project steady growth over the forecast period.
• Transcatheter Heart Valve Replacement (TAVI) Market Structure Analysis: The report provides detailed information about market the concentration of key players and tier analysis in the Transcatheter Heart Valve Replacement (TAVI) market. It also categories market players as per Tier 1, Tier 2, and Tier 3 in terms of their percentage share and product portfolio.
• Transcatheter Heart Valve Replacement (TAVI) Category & Segment Level Analysis: FMI’s category & segment level analysis provides insights into key factors affecting the market growth across various segments in terms of (segment 1), (segment 2), and (segment 3). It also uncovers critical opportunities across each segment to assist key players to capitalize on the,
• Transcatheter Heart Valve Replacement (TAVI) Market Trend Analysis: FMI’s market trend analysis provide compelling insights into current and upcoming trends in the healthcare industries. It also assists the industry players to identify potential trends to formulate a strategy to take advantage of these existing trends.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-537

Competitive Landscape Analysis

The latest study conducted by FMI provides in-depth insights into the global Transcatheter Heart Valve Replacement (TAVI) market to assist management level decision-makers in constructing a strategy to capitalize on the critical trends & opportunities. It also discloses competitive trends and profiles a list of leading players operating in the global Transcatheter Heart Valve Replacement (TAVI) market.

Scope Of Report

Report Attribute	Details
Growth rate	CAGR of 12% from 2022 to 2032
Base year for estimation	2021
Historical data	2015 – 2020
Forecast period	2022 – 2032
Quantitative units	Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032
Report coverage	Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,
Segments covered	Product, Surgical Approach, Application, Region
Regional scope	North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand
Country scope	U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa
Key companies profiled	Abbott, HighLife Medical, 4C Medical Technologies, JC Medical, LivaNova, Boston Scientific, Edwards Lifesciences, Medtronic plc, and Neovasc
Customization scope	Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Global Multi-item patient Monitor market demand is anticipated to be valued at US$ 39.0 Billion in 2022, forecast to grow at a CAGR of 3.61% to be valued at US$ 55.6 Billion from 2022 to 2032. A patient monitor is a medical device that consists a processing component, monitoring sensors and a screen display which further measures and store a patient’s vital signs such as, blood pressure, body temperature, respiratory rate and pulse rate.

Multi-item patient monitors are also capable of measuring the activity of different body organs and ensure higher level of quality patient care. Multi-item patient monitors are electronic and technological advancements use wireless and intelligent communication technology for monitoring the patient’s vitals.

These monitors display waveforms and numerical data for the patient and are used for treatment and diagnosis in different healthcare facilities, majorly for post-acute care and chronic diseases. Multi-item patient monitors are not only used in healthcare facilities but also for home-based care. These devices are portable and easy-to-use and thus are extensively being used in home-care settings as well.

Multi-item patient monitor Market: Drivers and Restraints 

Multi-item patient monitors are consistently being improved in technology, especially for better algorithm-based monitoring. Remote patient monitoring has evolved over the years and thus, boosted the demand for multi-item patient monitors over time.

Paradigm shift of multi-item patient monitors for use in hospitals to use in mobility services and ambulatory centers is expected to trigger the market growth for multi-item patient monitors during the forecast period. Several macro-economic factors like, increase in healthcare expenditure, improved healthcare infrastructure, and rise in disposable income are also expected to contribute to the market growth for multi-item patient monitors.

Growing product penetration and popularity across regions might also drive the multi-item patient monitors market. However, high costs associated with these monitors and poor reimbursement policies for the device might hinder the market growth for multi-item patient monitors during the forecast period.

These monitors also require maintenance and economic crisis in developing regions could also restraint the market growth for multi-item patient monitors over the forecast period.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-8489

Multi-item patient monitor Market: Overview 

Global Multi-item patient monitor market has witnessed growth due to increasing number of private healthcare facilities, globally. Multi-item patient monitor are being extensively used for emergency and post-acute care. Increase in adoption of portable multi-item patient monitors is also responsible for expansion of the multi-item patient monitors market.

Wireless technology for several monitors have gained U.S. FDA clearance and are being installed in various hospital settings around the globe. Improved technologies involve mobile augmented reality and wireless sensor network to remotely measure heart rate and body temperature in real time for patient care.

Multi-item patient monitors have gained popularity for home-based care, owing it to the easy-to operate feature of these monitors. Portable multi-item patient monitors have increased the demand of these monitors for emergency, critical and other ambulatory services.

Multi-item patient monitor Market: Region-wise Outlook 

Geography wise, Multi-item patient monitor market is divided into eight regions viz. North-America, Asia- Pacific excluding China & Japan, China, Japan, Western Europe, Eastern Europe, Latin America and Middle-East & Africa. North America’s Multi-item patient monitor market is expanding because of high product penetration and it will remain dominant during the forecast period because of growing number of intensive care facilities and improved healthcare infrastructure.

Southeast Asia is facing an increase in the trend for these monitors owing it to the use of multi-item patient monitors via Wi-Fi and other networks. Europe’s Multi-item patient monitor market is also expected to grow at a significant rate due to constant technological advancements in multi-item patient monitors and increase in number of private hospitals.

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-8489

Multi-item patient monitor Market: Key Market Participants 

Some of the market participants in the Global Multi-item patient monitor market identified across the value chain include: GE Healthcare, Mindray, NIHON KOHDEN CORPORATION, Koninklijke Philips N.V., OSI Systems, Inc, Microchip Technology Inc., Hipac Healthcare Pty Ltd, Arjo, Schiller, Heyer Medical AG, SUNRAY MEDICAL APPARATUS CO.LTD, TENKO MEDICAL, Drägerwerk AG & Co. KGaA and Fukuda Denshi

The research report on multi-item patient monitor presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on multi-item patient monitor provides analysis and information according to market segments such as geographies, application, and industry.

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Multiple government & non-government societies such as ASAA (American Sleep Apnea Association) and Circadian Sleep Disorder Networks have underpinned the growth of the sleep aid devices market by organizing various sleep cognizance programs pertaining to the importance of sound sleep. As a result, there has been a significant rise in the demand for sleep aid devices for the treatment of sleep-related disorders.

According to a recently published research report by Future Market Insights (FMI), the global sleep aid devices market is projected to be valued at US$ 29,200 Mn by the end of 2026. Increasing stress levels and rise in the sleeping disorders such as sleep deprivation, narcolepsy, restless legs syndrome, sleep apnea, and insomnia have necessitated the need for medical intervention. Among the various options available to healthcare providers and patients, the adoption of sleep aid devices has grown steadily.

Disposable income in the developing economies has been constantly increasing, which has upgraded the lifestyle of people. A sheer demand for advanced and secured sleep aid devices has been witnessed in these markets, on the back of enhanced spending capacity of the consumers. These factors have offered a lucrative growth opportunity to the manufacturers of these devices and as a result, the global sleep aid devices market is predicted to clock an impressive CAGR of over 4% by the end of 2026.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8956

Proclivity for Smoke and Alcohol Drives the Sales of Sleep Aid Devices at the Global Level

Increasing geriatric population and sleep disorders associated in this demography have created a robust demand for the sleep aid devices. Furthermore, a rise in the sedentary lifestyle and the comorbidities such as heart disease, obesity, stroke, type 2 diabetes, and atherosclerosis have resulted in the widespread utilization of sleep aid devices. Proclivity of adults for smoking, drug abuse, and alcohol at a global level have been a driving factor for the growth of the sleep aid devices market.

North America to Lead the Global Sleep Aid Devices Market, Europe Second Largest Market

As per the insights extracted from the descriptive study based on the sleep aid devices market, the market of Europe and North America reigns supreme on the back of reimbursement provided by the government. Moreover, a rise in the per capita medical expenditure of the consumers hailing from these regions has alongside contributed to the growth of the global sleep aid devices market.

As compared to the developed economies in North America and Europe, the sleep aid devices market in the emerging economies will witness an impressive rate of growth, on account of supportive government policies and ongoing development in the healthcare sector.

Comprehensive Look at the Competitive Landscape of the Global Sleep Aid Devices Market

Key information obtained from the market study includes an analytical view of the key players transforming the current sleep aid devices market scenario. This descriptive report highlights companies such as

• ResMed Inc.
• Sleep Number Corporation
• Koninklijke Philips N.V.
• Responsive Surface Technology LLC
• Simmons Bedding Company LLC
• Eight Sleep Inc.
• Electromedical Products International, Inc.
• Ebb Therapeutics
• Sleepace Inc.
• Kingsdown, Inc.
• Drive DeVilbiss Healthcare LLC
• SleepMed Inc.
• Cadwell Laboratories Inc.
• Teva Pharmaceutical Industries Ltd.
• Drive Medical Ltd.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-8956

Key companies such as Tempur Sealy International, Simmons Bedding Company LLC, Sleep Number Corporation, Dreams, ResMed, and Koninklijke Philips N.V. procure a major share in the sleep aid devices market. Aforementioned manufacturers are endeavoring into developing new products for diversifying their portfolio in the sleep aid devices market. Key manufacturers of sleep aid devices market are collaborating with retailers, distributors, and local wholesalers, in order to expand their operations

Domestic companies are competing depending on their channel management and pricing of the sleep aid devices. On the other hand, key players in the sleep aid devices market are concentrating their efforts on devising effective marketing strategies in order to increase the penetration of their products.

Table Of Content

• Executive Summary
  • Market Overview
  • Market Analysis
  • PMR Analysis and Recommendations
  • Wheel of Fortune

• Market Introduction
• Market Definition
• Market Taxonomy

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/8956

Sleep Aid  Devices Market Opportunity Analysis 

• Macro-Economic Factors
• Opportunity Analysis

 Market Background

• Value Chain Analysis
• Market Dynamics
• Drivers
• Supply Side Drivers
• Demand Side Drivers
• Restraints
• Key Trends

Global Economic Outlook

• 1. Gross Domestic Product by Region & Country, 2016 – 2021
• 2. Medical Devices Sector Outlook

1. Key Inclusions

• 1. Disease Epidemiology, Statistics
• 2. White Space Opportunities Narcolepsy and Obstructive Sleep Apnea Diseases
• 3. Technology Assessment

6.4. Regulatory Guidelines

6.5. Pricing Analysis

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-8956

1. North America Sleep Aid  Devices Market Analysis 2013–2017 and Forecast 2018–2026

•  Introduction
•  Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017
• Canada
• Market Size (US$ Mn) Forecast By Country, 2018–2026
•  Historical Market Value (US$ Mn) and Volume Units Trend Analysis By Product Type, 2013 –  2017

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The brain monitoring systems market is projected to expand at a healthy pace with global sales exceeding US$ 3.5 Bn by end of 2019, as per the latest research study by FMI. A range of broad factors, including the government funding for development of advanced medical devices, and favorable healthcare reimbursements are key sales influencers of brain monitoring devices.

The FMI report finds that rising prevalence of brain aneurysm and chronic brain injuries have necessitated adoption of brain monitoring systems expediting early and effective treatment. According to the Brain Aneurysm Foundation, nearly 6 million individuals in the U.S. suffer from unruptured brain aneurysm. In the wake of such alarming statistics, the adoption of brain monitoring systems is surging at an impressive rate for revolutionizing patient care.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1259

As per the study, demand for brain monitoring systems significantly took off in parallel with convergence of technology and healthcare, which translated into a massive influx of advanced medical devices with high functionality.

“Rising inclination toward non-invasive procedures is inducing a shift toward devices facilitating seamless observation and identification of neurons without involvement of invasive neurosurgery, such as brain monitoring systems,” says FMI report

The study opines EEG machines to gain significant momentum as widely-preferred brain monitoring systems, with revenues estimated to surpass US$ 1.5 Bn in 2019. Focus on delivering effective treatment via early detection of abnormalities have led the adoption of EEG machines, as these enable beneficial interventions with minimum chances of neurological complications. Simple platforms, effective report generator, and streamlined assessment tools are key attributes of EEGF machines that have driven their preference among patients and physicians alike.

Brain monitoring systems continue to witness significant demand from Hospitals (ICUS and adult care), with revenue expected to cross US$ 1 Bn in 2019. In response to high demand from hospitals, EEG machine manufacturers are implementing novel product development strategies, to realize enhanced profit margins.

Convergence of IOT with Brain Monitoring Space – A Key Trend Fostering Functionality with Better Connectivity

Penetration of IoT in the medical devices and systems landscape shows no signs of abating, evolving as a promising breakthrough that could result in connected ecosystems for brain monitoring devices with enhanced functionalities. IoT continues to play a major role in redefining interactions among various components of a brain monitoring system, thereby resulting in reduced costs, improved outcomes, and enhanced patient experiences. This trend is further complemented by on-going research efforts by prominent universities. For instance, a cohort of researchers at the Wits University of South Africa developed a way to connect human brains with internet on a real-time basis.

The transition toward miniaturized and portable models is gaining swift momentum in the brain monitoring systems landscape, as patients actively seek for advanced devices with new modalities, such as Functional Near-Infrared Spectroscopy (fNIRS), which enable real-time monitoring. The research study by FMI finds that future adoption of such upgraded versions will remain significant among physicians, as these facilitate seamless capture, storage, and processing of neurological information.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1259

Major players are making headway with strategic partnerships, acquisitions, and mergers to attain competitive advantages and access a wide-range range of resources and expertise. For instance, Philips acquired Electrical Geodesics, Inc. in 2017 with an objective to establish a new integrated neurological imaging, mapping and therapy guidance portfolio. Partnerships as such are foreseen to help in organic growth of the market players via collaborative innovations.

The FMI report covers assessment and forecast of the brain monitoring systems market for the period of 2018 to 2028. According to the report, the brain monitoring systems market is expected to grow at a CAGR of over 6% through 2028.

Competitive Landscape

This section of the report features profiles of key players operating in the brain monitoring systems market based on their market shares, differential strategies, brain monitoring systems product offerings, marketing approach and company dashboard.

Examples of some of the key players featured in this report include

Nihon Kohden Corporation., Electrical Geodesics, Inc. (Koninklijke Philips N.V.), Siemens Healthcare GmbH, Hitachi Ltd Natus Medical Incorporated, Medtronic plc. Compumedics Ltd, Neurosoft, EB Neuro S.p.A, and Ricoh Company Ltd among others.

The key manufacturers of brain monitoring systems are focusing on marketing strategies to increase both their product portfolio as well as geographical presence. The company’s manufacturing brain monitoring systems are focused on pricing strategies in order to lead in the market for brain monitoring systems.

Some other key market strategies followed by brain monitoring systems manufacturers include distribution & collaboration agreements to increase product reach, partnering with local as well as global retailers, and long-term partnerships with ambulatory surgical centers, clinics, hospitals and other distributor channels such as neonatal and pediatrics ICUs

Key Segment

Based on product type

fNIRS

EEG Systems

MEG Systems

MRI Systems

other brain monitoring systems

Based on modality

Portable/Handheld Systems

Standalone Systems

Based on end-users

hospitals

ambulatory surgical centers

clinics

pediatric & neonatal intensive care units

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1259

Based on region

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

China

Japan

MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The 3D cell culture market revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

• A steady rise in global research and development expenditure
• Efforts to leverage the potential of 3D cell culture to replace animal model testing
• Increasing demand for biosimilar products
• Extensive application of stem cell research and a growing emphasis on regenerative medicine

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material – natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

“While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years,” says FMI.

Leading Manufacturers in the 3D Cell Culture Market:

• Thermo Fisher Scientific Inc.,
• Merck KGaA,
• Becton,
• Dickinson and Company, and Lonza,
• Corning Incorporated,
• Synthecon, Inc.

Competitive Landscape of the Global 3D Cell Culture Market

The competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.

The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.

Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

Revenues in North America Continue to Surge

North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.

Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.

Key Segment Based on product type

• scaffold-free 3D cell culture
• scaffold-based 3D cell culture

Based on application

• drug discovery
• tissue regeneration & regenerative medicines
• cancer research
• stem cell technology
• others

Based on end user

• biotechnology and pharmaceuticals industries
• hospital laboratories
• academic research and institutes
• contract research organizations

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[207 Pages Report] A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2022 and ahead.

Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Report tracks key factors driving revenue growth of the market –

• Increasing prevalence of cancers
• Early diagnosis, promising improved chances of positive outcomes
• Fostering R&D funds supporting cancer research
• Strong product pipeline
• Bolstering adoption of chemo-radiotherapy in cancer treatment

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

• Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
• Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars – Epogen and Neupogen, and Neulasta respectively.

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelosuppression treatment landscape.  The report in a distinct section covers some of the key competitors operating in radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, in an effort to achieve better penetration into regional markets.

Enquiry/Query @ https://www.futuremarketinsights.com/ask-question/rep-gb-8116

Radiation-Induced Myelosuppression Treatment Market by Category

Indication: 

• Neutropenia
• Anemia
• Thrombocytopenia

Drug Class:

• Growth factors
• Erythropoietin stimulating agents
• Thrombopoietic agents
• Iron supplements

Route of Administration:

• Oral
• Injectable

Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Drug stores

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Increasing acceptance of therapeutic nuclear medicines (or radiopharmaceuticals) among industry experts will remain a prominent factor encouraging their adoption. Though associated with a negligible risk factor, radiopharmaceuticals are likely to witness growing recommendation owing to no proven significant adverse effects.

In the backdrop of the growing criticality of a more reliable, safer, and lesser harmful line of treatment for cancers, therapeutic nuclear medicines are being increasingly perceived as the potential treatment for cancer patients. Moreover, consistently surging instances of bone metastases further supports adoption growth, in the therapeutic nuclear medicines market.

Competitive Landscape

The competition section of the therapeutic nuclear medicines market report features the profiles of the key players of the therapeutic nuclear medicines market based on their product offerings, market shares, marketing approach and differential strategies.

Prominent Players:

• Bayer AG
• Novartis AG
• GE Healthcare
• Curium Pharmaceuticals
• Jubilant DraxImage
• Spectrum Pharmaceuticals
• Progenics Pharmaceuticals, Inc.
• ANSTO
• Lantheus Medical Imaging, Inc.
• Eckert & Ziegler
• International Isotopes Inc.

Just-under 10% Annual Growth Projected for Radiopharmaceuticals Adoption

A recent market research intelligence by Future Market Insights focuses on the deep-dive evaluation of global therapeutic nuclear medicines landscape, emphasizing the analysis of the most influential factors responsible for surging acceptance of radiopharmaceuticals in treating a range of cancers and a few other chronic conditions.

The study projects robust progress for the global radiopharmaceuticals market in coming years, reportedly driven by remarkable adoption in the treatment of prostate cancer. In 2019, the global demand for therapeutic nuclear medicines is expected to grow at a 9.7% annual rate, and maximum adoption is estimated by cancer research institutes at a global level.

• North America, jointly with Western Europe, represents more than 65% share of the total market value.
• Outpacing developed regional markets, the radiopharmaceuticals market in China and emerging economies across Asia Pacific, Latin America, and Middle East & Africa are slated for higher year on year revenue growth of over 12% in 2019 and ahead.
• China is reportedly the most lucrative market for penetration of therapeutic nuclear medicines, which is attributed to an expanding cancer patient pool in the country and a consistently surging rate of radiopharmaceuticals recommendation.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2930

Top Three Companies Account for More than 87% Market Value Share

A highly consolidated marketplace, global therapeutic nuclear medicines landscape is dominated by Bayer AG that currently accounts for just-under 80% revenue share in market. The top three players include GE Healthcare and Novartis AG other than Bayer, which collectively cover over 87% of the total valuation of radiopharmaceuticals market. While exceptional sales and success rate of Xofigo have been prominently retaining Bayer’s top position in the global market, strategic acquisitions are identified to be the key strategy behind Novartis’ success at a global level.

Thorough assessment of the competitive landscape of global therapeutic medicines market reveals a few prominent developmental strategies adopted by a majority of key companies operating in radiopharmaceuticals landscape –

• Investments in R&D of targeted cancer therapeutics
• Stronger supply chain and more streamlined distribution network
• Improved flagship product sales
• Strategic collaborations with pharma/biopharmaceutical companies
• Contractual relationships with domestic/regional stakeholders
• Strategic deals with internationally recognized cancer research institutes

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2930

Over 20% Growth Forecast for Erbium-169

Radium-223 has been the highest recommended type of radionucleotide in radiopharmaceuticals market. While it currently accounts for a whopping 78% share in the global market revenue, it is more likely that Erbium-169 that has been witnessing higher traction in recent past would witness relatively higher revenue growth in coming years. The report forecasts over 20% year on year revenue growth for Erbium-169 in 2019.

Exceptional Growth Projections for Thyroid & Brain Cancer

While over half the global market value is accounted by the adoption of therapeutic nuclear medicines for treatment of prostate cancer, bone metastases also accounts for sizable revenue generation in the market. Brain tumor and thyroid cancer are likely to emerge highly lucrative targets for manufacturers of therapeutic nuclear medicines, according to the report.

Investments in R&D of targeted cancer therapeutics

Stronger supply chain and more streamlined distribution network

Improved flagship product sales

Strategic collaborations with pharma/biopharmaceutical companies

Contractual relationships with domestic/regional stakeholders

Strategic deals with internationally recognized cancer research institutes

Key Segment

Based on the treatment type

• Radium-223
• Iodine-131
• Leutitium-177
• Yttrium-90
• Samarium-153
• Strontium-89
• Rhenium-188+ Rhenium-186
• Erbium-169
• Phosphorus-32
• Others

Based on the indication

• prostate cancer
• painful bone metastases
• thyroid cancer
• neuroblastoma
• synovitis
• non-Hodgkins lymphoma
• hepatic metastases
• brain tumour
• others

Based on the distribution channel

• hospitals
• ambulatory surgical centres
• cancer research institutes

For in-depth insights, Download a PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2930

Based on the region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia-Pacific Excluding Japan (APECJ)
• China
• Japan
• Middle East & Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs